Cytometry Part B: Clinical Cytometry最新文献

{"title":"Issue highlights—September 2026","authors":"Bruno Brando","doi":"10.1002/cyto.b.70056","DOIUrl":"https://doi.org/10.1002/cyto.b.70056","url":null,"abstract":"","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":"110 5","pages":"317-320"},"PeriodicalIF":2.9,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148942889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DinoFlow: Self-supervised pretraining in flow cytometry enables accurate detection of common hematopathological disorders","authors":"Brendan O'Fallon,&nbsp;Muir Morrison,&nbsp;Mattia Medina Grespan,&nbsp;Nicholas C. Spies,&nbsp;David P. Ng","doi":"10.1002/cyto.b.70043","DOIUrl":"10.1002/cyto.b.70043","url":null,"abstract":"<p>Flow cytometry is an essential component of routine hematological lab testing. Many computational methods have been proposed for the analysis of flow cytometry data, but most have focused on supervised learning for just one or a few specific disorders. To maximize clinical utility, we develop a method that enables identification of multiple common disorders and quality indicators. Our method includes a self-supervised pretraining component as well as a new, transformer-based model architecture. The self-supervised training algorithm is based on the DINO method while the model architecture is a relatively simple transformer encoder stack that includes a class (CLS) token, similar to BERT or vision-transformer models. Using a dataset of 52,625 samples obtained during routine clinical testing at our laboratory, we show that our pretraining method develops informative tube-level representations that clearly separate important diagnostic classes. We then evaluate performance on multiple downstream tasks, including sample viability estimation and five common hematological disorders. We compare our method to self-organizing maps, convolutional neural networks, attention-based multiple-instance learning models, and two varieties of set-transformer-based models, and demonstrate that our method delivers higher classification performance than other approaches.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":"110 5","pages":"347-358"},"PeriodicalIF":2.9,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cyto.b.70043","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standardizing stem cell enumeration: A methodological comparison of single and dual flow cytometry platforms","authors":"Hind Shakah,&nbsp;Alaa Alwahidi,&nbsp;Lara Sarhan,&nbsp;Habibah AlAittan,&nbsp;Saleh Khudirat,&nbsp;Ohood Hammad,&nbsp;Maysa Al-Hussaini","doi":"10.1002/cyto.b.70034","DOIUrl":"10.1002/cyto.b.70034","url":null,"abstract":"<p>Two flow cytometry methods are used for stem cell (CD34⁺) enumeration; single platform (SP) and dual platform (DP). While several studies reported comparable results, others suggested superiority of the SP method. This study evaluated variations between both methods using a modified workflow. A total of 54 fresh and thawed specimens, including mobilized peripheral blood, apheresis products, and umbilical cord blood, were analyzed using both methods. High concordance between SP and DP methods was observed for absolute viable CD34⁺ counts in fresh and thawed specimens (<i>p</i> = 0.088 and 0.427, respectively), as well as for CD34⁺ viability (<i>p</i> = 0.085 and 0.801). Absolute viable WBC counts were comparable between methods in thawed specimens (<i>p</i> = 0.124), whereas a modest statistical variation was observed in fresh specimen group (<i>p</i> = 0.039), largely influenced by umbilical cord blood samples. Variation in absolute viable CD34⁺ counts remained within clinically acceptable limits, with median variations of 2.4 for fresh and 1.4 for thawed samples. SP and DP methods demonstrated high concordance for absolute viable CD34⁺ enumeration and CD34⁺ viability in fresh and thawed specimens. Although a modest variation in viable WBC counts was observed in fresh samples, this did not affect CD34⁺ enumeration and remained clinically acceptable. While SP provides a standardized approach, the DP method offered greater gating flexibility, with fewer technical resources required, and was approximately 70% more cost-effective, supporting its use as a practical alternative in appropriate laboratory settings.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":"110 5","pages":"369-379"},"PeriodicalIF":2.9,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What is the optimal threshold for aberrant lymphoblasts at diagnosis to predict lymphoid transformation in chronic myeloid leukemia?","authors":"Zhenzhen Jiang,&nbsp;Mei Bao,&nbsp;Xiaoshuai Zhang,&nbsp;Yazhen Qin,&nbsp;Yazhe Wang,&nbsp;Qian Jiang","doi":"10.1002/cyto.b.70046","DOIUrl":"10.1002/cyto.b.70046","url":null,"abstract":"<p>We investigated the prognostic value of aberrant lymphoblasts (ALB) detected by flow cytometry (FCM) for predicting lymphoid transformation in patients with newly diagnosed chronic myeloid leukemia (CML). Data from patients with chronic phase CML were retrospectively interrogated to analyze covariates associated with lymphoid transformation-free survival (LTFS) via Cox, Firth-penalized Cox, Inverse Probability of Treatment Weighting-weighted Cox, and Fine-Gray competing risk regression approaches. Among 1081 patients, with a median follow-up of 43 (IQR, 16–70) months, 84 (8%) transformed to lymphoid or myeloid blast phase (LBP, 3%; MBP, 5%). 5-year cumulative incidence of lymphoid transformation and probabilities of LTFS, transformation-free survival and survival were 4% (95% CI, 3%–5%), 96% (95%–97%), 91% (89%–93%), and 95% (93%–96%), respectively. In the 54 patients (5%) with detectable ALB (median 0.3%; IQR, 0.1%–1.1%) at diagnosis, 24 (44%) transformed to LBP, none transformed to MBP. 0.4% ALB was identified as the optimal cutoff for LTFS by X-tile analysis and the maximally selected rank statistics method. All patients were stratified into ALB low- (ALB = 0), intermediate- (0&lt; ALB &lt; 0.4%), and high-risk (ALB ≥0.4%) groups with significant differences in 5-year probabilities of lymphoid transformation (2% [95% CI, 1%–2%] vs. 18% [3%–32%] vs. 91% [70%–100%]; <i>p</i>&lt; 0.001) and LTFS (98% [98%–99%] vs. 82% [69%–98%] vs. 9% [2%–49%]; <i>p</i>&lt; 0.001). Multivariable analyses confirmed that ALB intermediate-/high-risk groups and higher white blood cell count at diagnosis were significantly associated with a higher likelihood of lymphoid transformation. Low-level ALB detected by FCM at diagnosis identifies patients with chronic phase CML at high risk for lymphoid transformation, especially those with ALB ≥0.4%.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":"110 5","pages":"335-346"},"PeriodicalIF":2.9,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148301164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HLA-DR-positive acute promyelocytic leukemia: A diagnostic pitfall in flow cytometry evaluation","authors":"Nagarjun Sai Jaine,&nbsp;Beena Chandrasekhar,&nbsp;Sunanda Bharadwaj,&nbsp;Sunny Kumar Maurya","doi":"10.1002/cyto.b.70018","DOIUrl":"10.1002/cyto.b.70018","url":null,"abstract":"","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":"110 5","pages":"391-393"},"PeriodicalIF":2.9,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146200466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimization and validation of a flow cytometry-based HLA-B27 assay on BD FACSLyric","authors":"Azzeddine Tahiat,&nbsp;Fethi Meçabih,&nbsp;Houssam Boumzou,&nbsp;Halla Benkortbi,&nbsp;Nabila Attal,&nbsp;Kamel Djenouhat","doi":"10.1002/cyto.b.70031","DOIUrl":"10.1002/cyto.b.70031","url":null,"abstract":"<p>The BD™ HLA-B27 GS145.2-based assay for flow cytometric HLA-B27 typing has been validated on earlier-generation cytometers but not on the increasingly adopted BD FACSLyric platform, highlighting the need for platform-specific validation. While prior transfer strategies relied on conversion of the source instrument's parameters, we performed a <i>de novo</i> analytical validation of the HLA-B27 Kit on the FACSLyric. Our strategy encompassed determination of the assay's gray zone and rigorous evaluation of analytical performance following CLSI H62 guidelines. A total of 125 patient samples were analyzed in parallel by real-time PCR (RT-PCR) and flow cytometry. Sixteen patients (12.8%) were HLA-B27 positive by RT-PCR. A ROC-derived mean fluorescence intensity (MFI) cut-off of 6627 achieved 100% sensitivity and 99.1% specificity. The empirically defined gray zone (6627–7073) was narrow, encompassing only two samples. To strengthen analytical robustness, bootstrapping was applied to derive a 95% confidence interval around the cut-off, yielding an expanded gray zone of 5779–7327. Using this interval, 7 samples (5.6%) were classified as equivocal, comprising four HLA-B27-positive cases and three samples carrying cross-reactive alleles (HLA-B*42, HLA-B*37, and HLA-B*44). Outside the gray zone, flow cytometry showed complete concordance with RT-PCR. MFI values above 7327 ensured unequivocal HLA-B27 positivity with 100% specificity. Precision was high (intra-assay 5.43%, between-run 1.84%, between-day 5.13%), with no carryover and reliable typing up to 24 h post-collection. These results establish a robust, reproducible, and scalable framework for accurate first-line HLA-B27 detection on the FACSLyric platform.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":"110 5","pages":"380-387"},"PeriodicalIF":2.9,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147632839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of CD123 expression by mast cells in systemic mastocytosis with multicolor flow cytometry","authors":"Ryan C. Shean,&nbsp;Tracy I. George,&nbsp;David P. Ng","doi":"10.1002/cyto.b.70023","DOIUrl":"10.1002/cyto.b.70023","url":null,"abstract":"<p>Systemic mastocytosis (SM) is a clonal mast cell (MC) disorder characterized by aberrant immunophenotypes, including expression of CD25, CD2, and occasionally CD30. CD123, the α-subunit of the interleukin-3 receptor, is a therapeutic target in hematologic malignancies and has been reported to be expressed on neoplastic MCs by immunohistochemistry (IHC) with prognostic implications. This study aims to characterize CD123 expression in SM by flow cytometry. We retrospectively analyzed 142 bone marrow samples from 79 SM patients (81 diagnostic samples) and 25 controls with normal MC immunophenotype. Flow cytometry was performed using a clinically validated 9-color mast cell tube which included CD123. Data collected included SM subtype, clinical and laboratory features, MC burden, and marker expression. Statistical analyses were performed in R. CD123 was expressed on MCs in 91% of SM cases (ISM 92%, SM-AHN 94%, SSM 100%, ASM 100%, MCL 50%). Median percentage of MCs positive for CD123 was 53.9% (IQR 8.1–83.4). Compared to prior IHC data (overall 64% positivity), flow cytometry demonstrated more cases with CD123 expression by MCs. No significant correlations were observed between CD123 expression and serum tryptase, <i>KIT</i> D816V allele burden, or MC burden. CD123 is frequently expressed on neoplastic MCs in SM by flow cytometry, across all subtypes. These findings support further investigation of CD123 as a therapeutic target and warrant correlation with IHC and clinical outcomes in larger cohorts.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":"110 5","pages":"326-334"},"PeriodicalIF":2.9,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cyto.b.70023","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147479922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of immunophenotypic changes in acute megakaryoblastic leukemia after treatment","authors":"Ting Li,&nbsp;Man Chen,&nbsp;Ping Wu,&nbsp;Aixian Wang,&nbsp;Xiuyun Zhao,&nbsp;Minjing Fu,&nbsp;Xueying Wu,&nbsp;Junyi Zhen,&nbsp;Meiwei Gong,&nbsp;Wei Wang,&nbsp;Hui Wang","doi":"10.1002/cyto.b.70022","DOIUrl":"10.1002/cyto.b.70022","url":null,"abstract":"<p>Antigen expression on residual blast cells in acute megakaryoblastic leukemia (AMKL, classified as AML-M7 by FAB criteria) may change after treatment, potentially affecting both immunophenotypic characterization and minimal/measurable residual disease (MRD) monitoring. This study aimed to characterize post-therapy immunophenotypic alterations in AMKL and to determine whether specific patterns of antigenic change exist between samples obtained at initial presentation (IP group) and those obtained at MRD-positive status after therapy (MRD group). This retrospective descriptive study included 110 patients diagnosed with AMKL at Hebei Yanda Lu Daopei Hospital between January 1, 2009 and December 31, 2024 (male:female = 57:53; 103 pediatric and 7 adult cases). Immunophenotypes at initial diagnosis and after treatment were analyzed by flow cytometry. The chi-square test was used to compare antigen expression between the IP and MRD groups. Flow cytometric immunophenotypes differed by at least three antigens (including CD33, CD61, and CD42b) between initial presentation and post-therapy samples. Compared with the IP group, the MRD group showed a significantly higher frequency of loss of megakaryocytic markers, including CD61 (11/109, 10.1% vs. 30/109, 27.5%; <i>p</i> &lt; 0.05) and CD42b (6/106, 5.7% vs. 22/101, 21.8%; <i>p</i> &lt; 0.05). Partial loss of CD13 expression was also more frequent in the MRD group (18/99, 18.2% vs. 2/83, 2.4%; <i>p</i> &lt; 0.05). No significant differences were observed in the expression of progenitor-associated markers (CD34, CD117), myeloid markers (CD33, CD11b), or other antigens (HLA-DR, CD7, CD56, CD42a) between the two groups (<i>p</i> &gt; 0.05). Lineage-specific markers MPO and CD22, the monocytic marker CD14, and lymphoid markers CD10 and CD5 were negative in both groups. In contrast, aberrant expression of cCD3 (2/89, 2.2%) and CD19 (3/85, 3.5%) was observed in a small subset of IP cases. Overall, 100 of 110 patients (90.9%) showed changes in at least one antigen after therapy. By lineage category, alterations were most frequent in megakaryocytic markers (CD61, CD42b, CD41a, CD42a; 64/110, 58.2%), followed by myeloid antigens (HLA-DR, CD33, CD13, CD11b; 54/108, 50.0%), progenitor-associated antigens (CD34, CD117; 53/110, 48.2%), and lymphoid antigens (CD7, CD56; 24/107, 22.4%). In addition, CD110 was consistently expressed in all 26 AMKL cases tested, whereas only 18% (9/50) of non-AMKL AML cases were CD110-positive (<i>p</i> &lt; 0.05). Significant immunophenotypic differences, particularly involving CD61, CD42b, and CD13, exist between IP and MRD samples in AMKL. Antigenic shifts affecting megakaryocytic, myeloid, progenitor-associated, and lymphoid markers are common after chemotherapy. For MRD assessment, the use of more specific megakaryocytic markers such as CD110, together with comprehensive multiparameter flow cytometry panels, may improve detection accuracy.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":"110 5","pages":"359-368"},"PeriodicalIF":2.9,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147431360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COMIP-002: 27-color flow cytometry for measurable residual disease detection in B-cell lymphoblastic leukemia","authors":"Ryan C. Shean,&nbsp;Patricia Davis,&nbsp;Jeffery Jacobsen,&nbsp;David P. Ng","doi":"10.1002/cyto.b.70044","DOIUrl":"10.1002/cyto.b.70044","url":null,"abstract":"&lt;p&gt;This 27-color flow cytometry panel detects measurable residual disease from the bone marrow of patients who have been treated for B lymphoblastic leukemia (Table 1). As many targeted therapies exist, conventional 6 or 10-color flow cytometry (Borowitz et al., &lt;span&gt;2008&lt;/span&gt;) may struggle to differentiate normal regenerating immature B-cells from residual leukemic B-cells, particularly in the context of anti-CD19/CD22 directed immunotherapies.&lt;/p&gt;&lt;p&gt;Bispecific antibodies, CD19 or CD22 directed immunotherapies, and CAR-T therapies have led to increased survival in the treatment of B-cell lymphoblastic leukemia (B-ALL) (Zupanec et al., &lt;span&gt;2025&lt;/span&gt;). An important factor in evaluating treatment response is monitoring minimal/MRD (Borowitz et al., &lt;span&gt;2008&lt;/span&gt;). However, it is well known that after treatment with targeted immunotherapy leukemic cells can decrease expression of lineage and population defining markers commonly targeted (e.g., CD19, CD20, CD22, etc.) due to clonal selection pressures (Wudhikarn et al., &lt;span&gt;2022&lt;/span&gt;).&lt;/p&gt;&lt;p&gt;Sequencing-based MRD detection can provide reliable results regardless of the specific antigen expression on leukemia cells and offers a limit of detection of as low as 0.001% but requires an initial diagnostic sample to determine the characteristic immunoglobulin gene sequence. Sequencing-based MRD does not provide data concerning targetable antigen expression. On the other hand, MRD detection based on multi-color flow cytometry has been established as a fast and cost-effective method of assessing treatment response. With sufficient event acquisition, flow cytometric MRD detection can reach a similar limit of detection while simultaneously informing immunotherapy selection.&lt;/p&gt;&lt;p&gt;In patients with targeted anti CD19 therapy (e.g., blinatumomab), the leukemic cells often downregulate CD19. Increased use of anti-CD19 agents and subsequent multi-color flow MRD analysis has led to the discovery of normal CD19 negative B-cell precursors, stage 0 hematogones. They are characterized by CD34+/CD22+/CD19− immunophenotype with bright CD81 and CD38 expression. They are physiologically present during normal marrow regeneration but can closely mimic CD19-negative leukemic blasts, particularly in patients treated with anti-CD19 therapies such as CAR-T or bispecific antibodies. Misinterpretation of these normal precursors as residual disease is a significant diagnostic challenge in MRD assessment by flow cytometry. Our spectral flow panel is specifically designed to address this challenge by incorporating a comprehensive set of markers that enable clear discrimination between stage 0 hematogones and leukemic blasts (Table 2).&lt;/p&gt;&lt;p&gt;After acquisition and sequential exclusion of doublets, erythrocytes, and debris, Viakrome 808 (Beckman Coulter, Miami, FL) is used as a fixable viability dye to restrict further analysis to viable cells (Figure 1a). Then, a Boolean gate consisting of CD19+ or CD72+ (Buldini et al., &lt;s","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":"110 5","pages":"321-325"},"PeriodicalIF":2.9,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cyto.b.70044","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148175569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spurious binding of fluorochrome phycoerythrin-cyanine 5.5 (PE-Cy5.5) to B-cell lymphoma cells: A case study","authors":"Jessica M. Hughes,&nbsp;Joo Y. Song,&nbsp;Winston Y. Lee,&nbsp;Raju K. Pillai,&nbsp;Elizabeth M. Quirk,&nbsp;Hasmin Cada,&nbsp;Lorinda A. Soma","doi":"10.1002/cyto.b.70024","DOIUrl":"10.1002/cyto.b.70024","url":null,"abstract":"","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":"110 5","pages":"388-390"},"PeriodicalIF":2.9,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147442830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}